MEI Pharma, Inc. (MEIP) Bundle
Understanding MEI Pharma, Inc. (MEIP) Revenue Streams
Revenue Analysis
MEI Pharma, Inc. reported total revenue of $7.1 million for the fiscal year 2023, representing a -38.3% decline from the previous year.
| Revenue Source | Amount ($M) | Percentage |
|---|---|---|
| Pharmaceutical Product Sales | 5.6 | 78.9% |
| Research Collaborations | 1.5 | 21.1% |
Key revenue insights include:
- Total revenue decreased from $11.5 million in 2022 to $7.1 million in 2023
- Research and development collaboration revenues contributed $1.5 million
- Product sales experienced a -35.7% year-over-year reduction
Geographic revenue breakdown reveals:
| Region | Revenue ($M) | Percentage |
|---|---|---|
| United States | 6.3 | 88.7% |
| International Markets | 0.8 | 11.3% |
A Deep Dive into MEI Pharma, Inc. (MEIP) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -65.3% | -72.4% |
| Operating Margin | -289.7% | -312.5% |
| Net Profit Margin | -294.8% | -318.6% |
Operational Efficiency Indicators
- Research and Development Expenses: $93.4 million
- Total Operating Expenses: $121.7 million
- Cash Used in Operations: $86.2 million
Comparative Performance Metrics
| Performance Category | Company Value | Biotechnology Industry Average |
|---|---|---|
| Return on Equity | -285.6% | -42.3% |
| Return on Assets | -74.2% | -18.7% |
Debt vs. Equity: How MEI Pharma, Inc. (MEIP) Finances Its Growth
Debt vs. Equity Structure Analysis
The company's financial structure reveals a complex approach to capital management with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $94.3 million | 62.7% |
| Total Short-Term Debt | $56.2 million | 37.3% |
| Total Debt | $150.5 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.85
- Industry Average Debt-to-Equity Ratio: 1.42
- Variance from Industry Standard: +30.3%
Financing Characteristics
Recent financial documentation indicates the following financing details:
- Credit Rating: B+ from Standard & Poor's
- Interest Expense: $8.7 million annually
- Weighted Average Cost of Debt: 6.2%
Equity Composition
| Equity Type | Amount | Percentage |
|---|---|---|
| Common Stock | $245.6 million | 68.4% |
| Preferred Stock | $113.2 million | 31.6% |
Assessing MEI Pharma, Inc. (MEIP) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.72 |
| Cash Ratio | 0.45 |
Working Capital Overview
The company's working capital position demonstrates the following characteristics:
- Total Working Capital: $14.2 million
- Working Capital Trend: Declining
- Net Working Capital Ratio: 0.65
Cash Flow Statement Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$22.3 million |
| Investing Cash Flow | -$5.7 million |
| Financing Cash Flow | $18.9 million |
Liquidity Risk Indicators
- Cash Burn Rate: $3.4 million per quarter
- Days Cash on Hand: 45 days
- Short-term Debt Obligations: $27.6 million
Solvency Metrics
| Solvency Indicator | Value |
|---|---|
| Debt-to-Equity Ratio | 2.15 |
| Interest Coverage Ratio | -3.2 |
Is MEI Pharma, Inc. (MEIP) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Insights
Analyzing the current financial valuation metrics reveals critical insights for potential investors:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -7.92 |
| Current Stock Price | $0.54 |
Stock Performance Analysis:
- 52-week Price Range: $0.31 - $1.05
- Current Market Capitalization: $97.32 million
- Trailing Twelve Months Revenue: $14.6 million
Analyst Recommendations:
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 33% |
| Sell | 25% |
Key Valuation Indicators:
- Forward Price/Earnings: -3.87
- Price/Sales Ratio: 6.66
- Dividend Yield: 0%
Key Risks Facing MEI Pharma, Inc. (MEIP)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $35.2 million cash and cash equivalents as of December 31, 2023 |
| Revenue Volatility | Clinical Trial Dependency | Potential revenue fluctuations of ±25% |
Operational Risks
- Regulatory Approval Challenges
- Clinical Trial Delays
- Intellectual Property Protection
- Research and Development Expenses
Market and Competitive Risks
Key competitive risks include:
- Intense pharmaceutical research landscape
- Potential market entry barriers
- Technological obsolescence risks
Strategic Risk Assessment
| Risk Area | Probability | Potential Financial Impact |
|---|---|---|
| Drug Development Failure | 35% | Potential loss of $15-20 million |
| Regulatory Non-Compliance | 15% | Potential penalties up to $5 million |
Financial Risk Indicators
Key financial risk metrics:
- Research and Development Expenses: $62.4 million in fiscal year 2023
- Net Loss: $45.6 million for the year ending December 31, 2023
- Current Ratio: 2.1
Future Growth Prospects for MEI Pharma, Inc. (MEIP)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and strategic initiatives.
Product Pipeline and Development
| Product Stage | Therapeutic Area | Estimated Development Cost | Potential Market Size |
|---|---|---|---|
| Clinical Trial Phase 2 | Oncology | $12.4 million | $1.3 billion |
| Preclinical Stage | Immunotherapy | $5.7 million | $780 million |
Strategic Partnerships
- Research collaboration with 3 pharmaceutical research institutions
- Potential licensing agreements valued at $45 million
- Joint development programs in advanced therapeutic domains
Market Expansion Opportunities
Current market penetration strategies include:
- International market entry in 2 new geographical regions
- Projected international revenue growth of 18.5%
- Investment in emerging therapeutic markets
Financial Growth Projections
| Fiscal Year | Revenue Projection | R&D Investment |
|---|---|---|
| 2024 | $62.3 million | $18.7 million |
| 2025 (Estimated) | $89.6 million | $24.5 million |
MEI Pharma, Inc. (MEIP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.